MedPath

Treatment of severe hypertension in end-stage renal failure: Effect of renal denervation in dialysis patients and patients with renal transplant.

Phase 4
Conditions
high blood pressure
hypertension
10038430
10057166
Registration Number
NL-OMON39799
Lead Sponsor
Albert Schweitzer Ziekenhuis
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Pending
Sex
Not specified
Target Recruitment
30
Inclusion Criteria

Patients with a renal transplant or on dialysis with therapy resistent hypertension, as defined in current guidelines (SBP >160 mmHg with the use of >=3 antihypertensive medication).

Exclusion Criteria

Patient with a renal artery stent. Pregnant or pregnancy desire. Known allergy for iodine contrast. Age <18 year.
Patients with contraindication for MRI can participate. in these patients there will be no MRI examinations.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
<p>Primary study outcome is the degree of blood pressure drop in 6 months after<br /><br>renal denervation. Measurements will be performed with ambulatory blood<br /><br>pressure measurement during 24 hours. Also changes in medication regimen will<br /><br>be registered. </p><br>
Secondary Outcome Measures
NameTimeMethod
<p>Effect of renal denervation on cardiac mass and function. Changes in sympatic<br /><br>nerve activity measured by EMG of the nervus peroneus. Changes in hormonal<br /><br>levels related to blood pressure regulation.</p><br>
© Copyright 2025. All Rights Reserved by MedPath